Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19

doi:10.3969/j.issn.1673-8640.2023.12.007

Abstract

Abstract:

Objective To investigate the expression of anti-angiotensin-converting enzyme-2（ACE-2） antibody in patients with corona virus disease 2019（COVID-19） and its risk factors. Methods A total of 196 COVID-19 patients（COVID-19 group） were enrolled from Shanghai East Hospital of Tongji University from February to April 2023，which included 156 patients with infection（infection group） and 40 patients with recovery（rehabilitation group）. Totally，12 healthy subjects who were not infected with severe acute respiratory syndrome coronavirus 2（SARS-CoV-2） during the same period were enrolled as control group. The clinical data of all the subjects were collected，and anti-ACE-2 antibody and anti-SARS-CoV-2 IgG antibody were determined. Logistic regression analysis was used to evaluate the risk factors for anti-ACE-2 antibody. Results Compared with control group，the absorbance（A） value of anti-ACE-2 antibody in infection and rehabilitation groups were increased（P<0.05）. The A value was increased in mild，common，severe patients and dead patients with COVID-19（P<0.05），and that in dead group was the highest. The A value for serum anti-ACE-2 antibody in male patients was higher than that in female patients（P<0.05），and that in patients hospitalized for >27 d was higher than that in patients hospitalized for ≤27 d（P<0.05）. There was no statistical significance in serum anti-ACE-2 antibody A value between inpatients and outpatients during the infection period（P>0.05）. The anti-ACE-2 antibody level in inpatients was higher than that in outpatients in common group（P<0.05）. The positive rates of anti-ACE-2 antibody were 22.22% in common patients，27.50% in severe patients，38.71% in dead patients，31.82% in mild patients and 2.50% in recovery patients. Logistic regression analysis showed that the positive IgG of anti-SARS-CoV-2 antibody and increasing age were influencing factors for positive anti-ACE-2 antibody [odds ratios（OR） were 0.115 and 1.047，and 95% confidence intervals（CI） were 0.039-0.346 and 1.005-1.091，respectively]. Conclusions Anti-ACE-2 antibody is related to the severity of COVID-19 patients. Both age and anti-SARS-CoV-2 IgG antibody are influencing factors associated with anti-ACE-2 antibody.

Key words: Angiotensin-converting enzyme-2, Autoantibody, Coronavirus disease 2019, Severe acute respiratory syndrome coronavirus 2

CLC Number:

R446.1

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19[J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

Figures/Tables 5

References 24

[1]	MISHRA S K, TRIPATHI T. One year update on the COVID-19 pandemic:where are we now?[J]. Acta Trop, 2021, 214:105778. DOI URL
[2]	SHARMA O, SULTAN A A, DING H, et al. A review of the progress and challenges of developing a vaccine for COVID-19[J]. Front Immunol, 2020, 11:585354. DOI URL
[3]	HAMMING I, TIMENS W, BULTHUIS M L, et al. Tissue distribution of ACE-2 protein,the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis[J]. J Pathol, 2004, 203(2):631-637. DOI URL
[4]	VERDECCHIA P, CAVALLINI C, SPANEVELLO A, et al. The pivotal link between ACE-2 deficiency and SARS-CoV-2 infection[J]. Eur J Intern Med, 2020, 76:14-20. DOI URL
[5]	ZHANG H, PENNINGER J M, LI Y, et al. Angiotensin-converting enzyme 2(ACE-2)as a SARS-CoV-2 receptor:molecular mechanisms and potential therapeutic target[J]. Intensive Care Med, 2020, 46(4):586-590. DOI
[6]	ARTHUR J M, FORREST J C, BOEHME K W, et al. Development of ACE-2 autoantibodies after SARS-CoV-2 infection[J]. PLoS One, 2021, 16(9):e0257016.
[7]	LIU C, LUO R, ELLIOTT S E, et al. Elevated transglutaminase activity triggers angiotensin receptor activating autoantibody production and pathophysiology of preeclampsia[J]. J Am Heart Assoc, 2015, 4(12):e002323. DOI URL
[8]	CASCIOLA-ROSEN L, THIEMANN D R, ANDRADE F, et al. IgM autoantibodies recognizing ACE-2 are associated with severe COVID-19[J]. medRxiv, 2020.
[9]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL]. (2022-03-14)[2023-03-02]. http://www.nhc.gov.cn/cms-search/downFiles/ef09aa4070244620b010951b088b8a27.pdf.
[10]	ORONSKY B, LARSON C, HAMMOND T C, et al. A review of persistent post-COVID syndrome(PPCS)[J]. Clin Rev Allergy Immunol, 2023, 64(1):66-74. DOI
[11]	SHANG J, YE G, SHI K, et al. Structural basis of receptor recognition by SARS-CoV-2[J]. Nature, 2020, 581(7807):221-224. DOI
[12]	LAI Y C, CHENG Y W, CHAO C H, et al. Antigenic cross-reactivity between SARS-CoV-2 S1-RBD and its receptor ACE-2[J]. Front Immunol, 2022, 13:868724. DOI URL
[13]	WANG E Y, MAO T, KLEIN J, et al. Diverse functional autoantibodies in patients with COVID-19[J]. Nature, 2021, 595(7866):283-288. DOI
[14]	VERDECCHIA P, CAVALLINI C, SPANEVELLO A, et al. The pivotal link between ACE-2 deficiency and SARS-CoV-2 infection[J]. Eur J Intern Med, 2020, 76:14-20. DOI URL
[15]	GHEBLAWI M, WANG K, VIVEIROS A, et al. Angiotensin-converting enzyme 2:SARS-CoV-2 receptor and regulator of the renin-angiotensin system:celebrating the 20th anniversary of the discovery of ACE-2[J]. Circ Res, 2020, 126(10):1456-1474. DOI URL
[16]	GETACHEW B, TIZABI Y. Vitamin D and COVID-19:role of ACE-2,age,gender,and ethnicity[J]. J Med Virol, 2021, 93(9):5285-5294. DOI URL
[17]	LABANDEIRA C M, PEDROSA M A, QUIJANO A, et al. Angiotensin type-1 receptor and ACE-2 autoantibodies in Parkinson's disease[J]. NPJ Parkinsons Dis, 2022, 8(1):76. DOI
[18]	RODRIGUEZ-PEREZ A I, LABANDEIRA C M, PEDROSA M A, et al. Autoantibodies against ACE-2 and angiotensin type-1 receptors increase severity of COVID-19[J]. J Autoimmun, 2021, 2021:102683.
[19]	DE MARIA A. Anti-idiotype antibodies in SARS-CoV-2 infection and vaccination[J]. N Engl J Med, 2022, 386(9):897-898. DOI URL
[20]	RODRIGUES PRESTES T R, ROCHA N P, MIRANDA A S, et al. The anti-inflammatory potential of ACE-2/angiotensin-(1-7)/mas receptor axis:evidence from basic and clinical research[J]. Curr Drug Targets, 2017, 18(11):1301-1313.
[21]	CHEN J, JIANG Q, XIA X, et al. Individual variation of the SARS-CoV-2 receptor ACE-2 gene expression and regulation[J]. Aging Cell, 2020, 19(7):e13168. DOI URL
[22]	NAGY B Jr, FEJES Z, SZENTKERESZTY Z, et al. A dramatic rise in serum ACE-2 activity in a critically ill COVID-19 patient[J]. Int J Infect Dis, 2021, 103:412-414. DOI URL
[23]	MEHTA P, MCAULEY D F, MICHAEL B, et al. COVID-19:consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(10229):1033-1034. DOI URL
[24]	王斌. 中性粒细胞/淋巴细胞比值与新型冠状病毒肺炎短期不良预后的相关性[J]. 检验医学, 2021, 36(3):275-280.

组别	例数	年龄/岁	性别		合并基础疾病/例	吸烟史/例	高血压史/例	糖尿病史/例	SARS-CoV-2 IgG抗体阳性/例	就诊情况
组别	例数	年龄/岁	男/例	女/例	合并基础疾病/例	吸烟史/例	高血压史/例	糖尿病史/例	SARS-CoV-2 IgG抗体阳性/例	门诊/例	住院/例
正常对照组	12	70.30±6.32	7	5	8	1	1	1	10
感染期组	156		89	67	111	20	69	51	121	66	90
轻型	22	76.40±12.91	7	15	12	3	1	1	19	22	0
普通型	63	76.56±11.87	35	28	44	10	33	25	53	44	19
重型	40	80.36±9.09	27	13	30	5	23	14	28	0	40
死亡	31	81.54±8.60	20	11	25	2	12	11	21	0	31
康复期组	40	65.69±15.55	21	19	25	4	23	7	26
统计值		1.231	2.026		3.081	0.189	9.483	7.352	2.329
P值		0.179	0.363		0.214	0.910	0.009	0.025	0.312

组别	例数	年龄/岁	性别		合并基础疾病/例	吸烟史/例	高血压史/例	糖尿病史/例	SARS-CoV-2 IgG抗体阳性/例	就诊情况
组别	例数	年龄/岁	男/例	女/例	合并基础疾病/例	吸烟史/例	高血压史/例	糖尿病史/例	SARS-CoV-2 IgG抗体阳性/例	门诊/例	住院/例
正常对照组	12	70.30±6.32	7	5	8	1	1	1	10
感染期组	156		89	67	111	20	69	51	121	66	90
轻型	22	76.40±12.91	7	15	12	3	1	1	19	22	0
普通型	63	76.56±11.87	35	28	44	10	33	25	53	44	19
重型	40	80.36±9.09	27	13	30	5	23	14	28	0	40
死亡	31	81.54±8.60	20	11	25	2	12	11	21	0	31
康复期组	40	65.69±15.55	21	19	25	4	23	7	26
统计值		1.231	2.026		3.081	0.189	9.483	7.352	2.329
P值		0.179	0.363		0.214	0.910	0.009	0.025	0.312

项目	β值	OR值（95%CI）	P值
性别	-0.272	0.762（0.297~1.954）	0.572
高血压史	0.191	1.211（0.286~5.133）	0.795
糖尿病史	-0.003	0.997（0.321~3.090）	0.995
抗SARS-CoV-2 IgG抗体	-2.159	0.115（0.039~0.346）	0.000
吸烟	-0.425	0.654（0.176~2.430）	0.526
年龄	0.046	1.047（1.005~1.091）	0.027
基础疾病	1.321	3.748（0.584~24.059）	0.164

项目	β值	OR值（95%CI）	P值
性别	-0.272	0.762（0.297~1.954）	0.572
高血压史	0.191	1.211（0.286~5.133）	0.795
糖尿病史	-0.003	0.997（0.321~3.090）	0.995
抗SARS-CoV-2 IgG抗体	-2.159	0.115（0.039~0.346）	0.000
吸烟	-0.425	0.654（0.176~2.430）	0.526
年龄	0.046	1.047（1.005~1.091）	0.027
基础疾病	1.321	3.748（0.584~24.059）	0.164